drugset
drugset / Trial / NCT04284774

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774 ↗

Phase 2 Active not recruiting 5 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.

Timeline

Start
2020-10-13
Primary completion
2024-03-31
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject tipifarnib Small molecule 350 mg/m2 Oral

Indications

Ewing sarcoma Langerhans cell histiocytosis adrenal gland pheochromocytoma ectomesenchymoma ependymoma hepatoblastoma kidney Wilms tumor malignant germ cell tumor malignant glioma medulloblastoma melanoma neuroblastoma non-Hodgkin lymphoma osteosarcoma peripheral primitive neuroectodermal tumor rhabdoid tumor of the kidney rhabdomyosarcoma thyroid gland carcinoma